{
    "medicine_id": "9fb9c53c74be761f3511d254e93e55fa7fc1278d",
    "platform_id": "DB00298",
    "metadata": {
        "name": "Dapiprazole 25 mg 5mL Kit",
        "composition": "25 mg 5mL Dapiprazole",
        "clinical_particulars": {
            "therapeutic_indications": "Used in the treatment of iatrogenically induced mydriasis produced by adrenergic phenylephrine or parasympatholytic tropicamide agents used in certain eye examinations",
            "contraindications": {
                "disease": "Oral LD sub 50 sub is 1189 2100 mg kg in mice rats and rabbits",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Dapiprazole is an alpha adrenergic blocking agent It produces miosis by blocking the alpha adrenergic receptors on the dilator muscle of the iris Dapiprazole produces no significant action on ciliary muscle contraction and thus there are no changes in the depth of the anterior chamber of the thickness of the lens It does not alter the IOP either in normal eyes or in eyes with elevated IOP The rate of pupillary constriction may be slightly slower in clients with brown irises than in clients with blue or green irises",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB13946",
                        "description": "Testosterone undecanoate may increase the hypertensive activities of Dapiprazole"
                    },
                    {
                        "drugbank-id": "DB00924",
                        "description": "The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dapiprazole"
                    },
                    {
                        "drugbank-id": "DB01233",
                        "description": "The risk or severity of sedation can be increased when Metoclopramide is combined with Dapiprazole"
                    },
                    {
                        "drugbank-id": "DB11732",
                        "description": "The risk or severity of adverse effects can be increased when Lasmiditan is combined with Dapiprazole"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of adverse effects can be increased when Dapiprazole is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of CNS depression can be increased when Haloperidol is combined with Dapiprazole"
                    },
                    {
                        "drugbank-id": "DB06283",
                        "description": "The risk or severity of CNS depression can be increased when Dapiprazole is combined with Ziconotide"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "Dapiprazole may increase the central nervous system depressant CNS depressant activities of Fluoxetine"
                    },
                    {
                        "drugbank-id": "DB14881",
                        "description": "The risk or severity of hypotension sedation death somnolence and respiratory depression can be increased when Dapiprazole is combined with Oliceridine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}